严重乙肝相关肝病发病机理和治疗.pptVIP

HBV-associated Severe Liver Diseases:  Progress on Pathogenesis and Treatment ;The Progress of Pathogenesis Viral Factors;Evidence for the role of viral factors;HBV mutation and genotyping is closely related to disease severity;Fig. Frequencies of Precore/C-promoter mutations compared between pts. with FH and self-limited acute hepatitis who were infected with HBV/Bj or Ce ;Outcome of acute hepatitis B virus infection;Pathogenesis of Special Fulminant Hepatitis---- Immunosuppression-induced ALF(Fibrosing Cholastatic Hepatitis, FCH);Fig. Hepatitis reactivation after chemotherapy;Ocama P, et al. Am J Med, 2005, 118, Dec:e15-1413.e22 ;Why do the pts. in tolerance stage have no FCH manifestations ? ;Medical strategy for two categories of ALF;The Progress of Treatment Antiviral therapy by NA;Hospitalized pts. with HBV-associated hepatic failure in Our Dept. through 1991-2005;Fig. Hospitalized liver failure patient of hepatitis B and nucleoside analogue usage in South-West hospital; Outcome of severe hepatitis patients after LAM treatment ;Fig. Patient’s condition and prognosis of anti-HBV therapy within 1 week after onset of symptoms;Year(n);;Fig. liver failure of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy in South-West hospital;Fig. Anti-HBV therapy by NA of 276 liver failure patients of Hepatitis after anti-HBV therapy by NA;Fig. The disease cause of 1 patients with severe hepatitis B after treatment;HBV DNA (log10 copies/ml);Target sequence: 394 bp. located in the Rt region of the polymerase gene in HBV genome All known mutation loci associated with nucleoside analog resistance were included;Agarose gel electrophoresis of PCR products;;Patient I;Patient J;Antiviral therapy before and After OLTx in Pts. with Severe Hepatitis;Terrault N, et al. Liver Transpl, 2005, 11: 716-732; HBV recurrence rate between HBV DNA(+) and HBV DNA(-) pre-OLT patients;Mechanism for HBV recurrence post-OLTx;Conclusion: Progress of Pathoge